Synergistic interactions between interferon-{gamma} and TRAIL modulate c-FLIP in endothelial cells, mediating their lineage-specific sensitivity to thrombotic thrombocytopenic purpura plasma-associated apoptosis

Blood

Volumn 112, Issue 2, 2008, Pages 340-349

  Stefanescu, Radu ^a   Bassett, Dustin ^a   Modarresi, Rozbeh ^a   Santiago, Francisco ^a   Fakruddin, Mohamad ^b   Laurence, Jeffrey ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Aeras Global TB Vaccine Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 8; FLICE INHIBITORY PROTEIN; GAMMA INTERFERON; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; RECOMBINANT GAMMA INTERFERON;

APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TISSUE DISTRIBUTION; UBIQUITINATION; UPREGULATION; CELL CULTURE; CELL LINEAGE; CYTOLOGY; DRUG EFFECT; DRUG POTENTIATION; GENETICS; MICROCIRCULATION; PATHOLOGY; VASCULAR ENDOTHELIUM;

APOPTOSIS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELL LINEAGE; CELLS, CULTURED; DRUG SYNERGISM; ENDOTHELIUM, VASCULAR; HUMANS; INTERFERON-GAMMA, RECOMBINANT; MICROCIRCULATION; PURPURA, THROMBOTIC THROMBOCYTOPENIC; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 45549087679     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-10-119552     Document Type: Article

References (47)

1. Kwaan HC, Bennett CL. Thrombotic thrombocytopenic purpura-2005. Semin Thromb Hemost. 2005;31:611-613.
2. Kwaan HC. The pathogenesis of thrombotic thrombocytopenic purpura. Semin Throm Hemost. 1979;5:184-198.
3. Dang CT, Magid MS, Weksler B, Chadburn A, Laurence J. Enhanced endothelial cell apoptosis in splenic tissues of patients with thrombotic thrombocytopenic purpura. Blood. 1999;93:1264-1270.
4. Mitra D, Jaffe EA, Weksler B, Hajjar KA, Soderland C, Laurence J. Thrombotic thrombocytopenic purpura and sporadic hemolytic-uremic syndrome plasmas induce apoptosis in restricted lineages of human microvascular endothelial cells. Blood. 1997;89:1224-1234.
5. Robaye B, Mosselmans R, Fiers W, Dumont JE, Galand P. Tumor necrosis factor induces apoptosis (programmed cell death) in normal endothelial cells in vitro. Am J Pathol. 1991;138:447-453.
6. Wada H, Kaneko T, Ohiwa M, et al. Plasma cytokine levels in thrombotic thrombocytopenia purpura. Am J Hematol. 1992;40:167-170.
7. Fitzpatrick MM, Shah V, Trompeter RS, Dillon MJ, Barratt TM. Interleukin-8 and polymorphonuclear leukocyte activation in hemolytic uremic syndrome of childhood. Kidney Int. 1993;42:951-956.
8. Shariatmadar S, Nassiri M, Vincek V. Effect of plasma exchange on cytokines measured by multianalyte bead array in thrombotic thrombocytopenic purpura. Am J Hematol. 2005;79:83-88.
9. van de Kar NCAJ, Sauerwein RW, Demacker PNM, Grau GE, van Hinsbergh VWM, Monnens LAH. Plasma cytokine levels in hemolytic uremic syndrome. Nephron. 1995;71:309-313.
10. Qu L, Kiss JE. Thrombotic microangiopathy in transplantation and malignancy. Semin Thromb Hemost. 2005;31:691-699.
11. Saegusa Y, Ziff M, Welkovich L, Cavender D. Effect of inflammatory cytokines on human endothelial cell proliferation. J Cell Physiol. 1990;142: 488-495.
12. Kumar-Sinha C, Varambally S, Sreekumar A, Chinnaiyan AM. Molecular cross-talk between the TRAIL and interferon signaling pathways. J Biol Chem. 2002;277:575-585.
13. Volpert OV. Modulation of endothelial cell survival by an inhibitor of angiogenesis thrombospondin1: a dynamic balance. Cancer Metast Rev. 2000;19:87-92.
14. Sata M, Walsh K. Endothelial cell apoptosis induced by oxidized LDL is associated with the down-regulation of the cellular caspase inhibitor FLIP. J Biol Chem. 1998;273:33103-33106.
15. Molostvov G, Morris A, Rose P, Basu S. Modulation of Bcl-2 family proteins in primary endothelial cells during apoptosis. Pathophysiol Hemost Thromb. 2002;32:85-91.
16. Erwert RD, Winn RK, Harlan JM, Bannerman DD. Shiga-like toxin inhibition of FLICE-like inhibitory protein expression sensitizes endothelial cells to bacterial lipopolysaccharide-induced apoptosis. J Biol Chem. 2002;277:40567-40574.
17. Molostvov G, Morris A, Rose P, Basu S. Interaction of cytokines and growth factor in the regulation of verotoxin-induced apoptosis in cultured human endothelial cells. Br J Haematol. 2001; 113:891-897.
18. Breitschopf K, Haendeler J, Malchow P, Zeiher AM, Dimmeler S. Posttranslational modification of Bcl-2 facilitates its proteasome-dependent degradation: molecular characterization of the involved signaling pathway. Mol Cell Biol. 2000;20:1886-1896.
19. Mitra D, Kim J, MacLow C, Karsan A, Laurence J. Role of caspases 1 and 3 and Bcl-2-related molecules in endothelial cell apoptosis associated with thrombotic microangiopathies. Am J Hematol. 1998;59:279-287.
20. Laurence J, Mitra D, Steiner M, Staiano-Coico L, Jaffe E. Plasma from patients with idiopathic and human immunodeficiency virus-associated thrombotic thrombocytopenic purpura induce apoptosis in microvascular endothelial cells. Blood. 1996;87:3245-3254.
21. Kim J, Wu H, Hawthorne L, Rafii S, Laurence J. Endothelial cell apoptotic genes associated with the pathogenesis of thrombotic microangiopathies: an application of oligonucleotide genechip technology. Microvasc Res. 2001;62:83-93.
22. Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. Nature. 1997;388:190-195.
23. Hyer ML, Samuel T, Reed JC. The FLIP-side of Fas signaling. Clin Cancer Res. 2006;12:5929-5931.
24. Rieger J, Naumann U, Glaser T, Ashkenazi A, Weller M. APO2 ligand: a novel lethal weapon against malignant glioma? FEBS Lett. 1998;427: 124-128.
25. Mauro M, Costello C, Laurence J. Role of transforming growth factor β1 in microvascular endothelial cell apoptosis associated with thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome. Am J Hematol. 2001;66:12-22.
26. Herbeuval J-P, Boasso A, Grivel J-C, et al. TNFrelated apoptosis-inducing ligand (TRAIL) in HIV1-infected patients and its in vitro production by antigen-presenting cells. Blood. 2005;105:2458-2464.
27. Biancotto A, Grivel J-C, Iglehart SJ, et al. Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1. Blood. 2007;109:4272-4279.
28. Di Carlo BA, Stefanescu R, Lee K, et al. Association of complement with microvascular endothelial cell injury in thrombotic microangiopathy in vivo and in in vitro model systems [abstract]. Blood. 2006;108:424a. Abstract no. 1465.
29. Li JH, Kirkiles-Smith NC, McNiff JM, Pober JS. TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells. J Immunol. 2003;171:1526-1533.
30. Zhang XD, Nguyen T, Thomas WD, Sanders JE, Hersey P. Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Lett. 2000;482:193-199.
31. Kim S, Kang J, Evers M, Chung DH. Interferon-+ induces caspase-8 in neuroblastomas without affecting methylation of caspase-8 promoter. J Pediatr Surg. 2004;39:509-515.
32. kappa;B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-+/RANKL cross-talk. J Biol Chem. 2003;278:48251-48256.
33. Siegmund D, Wicovsky A, Schmitz I, et al. Death receptor-induced signaling pathways are differentially regulated by gamma interferon upstream of caspase 8 processing. Mol Cell Biol. 2005;25: 6363-6379.
34. Suhara T, Mano T, Oliveira BE, Walsh K. Phosphatidylinositol 3-kinase/Akt signaling controls endothelial cell sensitivity to Fas-mediated apoptosis via regulation of FLICE-inhibitory protein (FLIP). Circ Res. 2001;89:13-19.
35. Fukazawa T, Fujiwara T, Uno F, et al. Accelerated degradation of cellular FLIP protein through the ubiquitin-proteasome pathway in p53-mediated apoptosis of human cancer cells. Oncogene. 2001;20:5225-5231.
36. Bannerman DD, Tupper JC, Ricketts WA, Bennett CF, Winn RK, Harlan JM. A constitutive cytoprotective pathway protects endothelial cells from lipopolysaccharide-induced apoptosis. J Biol Chem. 2001;276:14924-14932.
37. Galbusera M, Noris M, Remuzzi G. Thrombotic thrombocytopenic purpura: then and now. Semin Thromb Hemost. 2006;32:81-89.
38. κB regulation enhance tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in virus-infected cells. J Biol Chem. 2003;278: 18092-18100.
39. Ruggenenti P. Post-transplant hemolytic-uremic syndrome. Kidney Int. 2002;62:1093-1104.
40. Gervasoni C, Ridolfo AL, Vaccarezza M, et al. Thrombotic microangiopathy in patients with acquired immunodeficiency syndrome before and during the era of introduction of highly active antiretroviral therapy. Clin Infect Dis. 2002;35:1534-1540.
41. Vesely SR, George JN, Lammle B, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003; 102:60-68.
42. Liabakk N-B, Espevik T. Monoclonal antibodies against TRAIL. Vitamins Hormones. 2004;67:65-79.
43. Ruiz-Torres MP, Casiraghi F, Galbusera M, et al. Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. Thromb Hemost. 2005;93:443-452.
44. Mauro M, Zlatopolskiy A, Raife TJ, Laurence J. Thienopyridine-linked thrombotic microangiopathy: association with endothelial cell apoptosis and activation of MAP kinase signaling cascades. Br J Haematol. 2004;124:200-210.
45. Secchiero P, Gonelli A, Carnevale E, et al. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation. 2003;107: 2250-2256.
46. Zhang XD, Franco A, Myers K, Gray C, Nguyen T, Hersey P. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res. 1999;59:2747-2753.
47. Cudrici C, Niculescu F, Jensen T, et al. C5b-9 terminal complex protects oligodendrocytes from apoptotic cell death by inhibiting caspase-8 processing and up-regulating FLIP. J Immunol. 2006; 176:3173-3180.